Nikolaos E Tzanakis, Department of Social Medicine & Thoracic Medicine, Medical School University of Crete, Crete 71110, Greece
Ioanna G Tsiligianni, General Practitioner, Agia Barvara Health Care Center, Heraklion, Crete 70003, Greece
Nikolaos M Siafakas, Department of Thoracic Medicine, Medical School University of Crete, Crete 71110, Greece
Author contributions: Tzanakis NE designed the study; Tzanakis NE and Tsiligianni IG performed the search strategy for identification of studies and wrote the article; Siafakas NM reviewed the article and gave relevant suggestions.
Correspondence to: Ioanna G Tsiligianni, MD, PhD, MPH, General Practitioner, Agia Barbara Health Care Centre, Heraklion, Crete 70003, Greece. email@example.com
Telephone: +30-2810-392855 Fax: +30-2810-542650
Received: September 3, 2009 Revised: December 3, 2009
Accepted: December 10, 2009
Published online: January 21, 2010
Inflammatory bowel disease (IBD) has been associated with either clinical or subclinical airway and parenchymal lung involvement and interstitial lung complications. Several studies have reported that atopy has a high prevalence in IBD patients. Overlapping allergic disorders seem to be present in both the respiratory and gastrointestinal systems. The purpose of this review is to update clinicians on recent available literature and to discuss the need for a highly suspicious approach by clinicians.
© 2010 Baishideng. All rights reserved.
Key words: Atopy; Inflammatory bowel disease; Pulmonary involvement
Peer reviewers: Dr. Zoran Krivokapic, Professor, MD, FRCS, Institute for Digestive Disease, First Surgical Clinic, Clinical Center of Serbia, 6, Dr Koste Todorovica, Belgrade, 11000, Serbia; Javier Martin, MD, PhD, Department of Immunology, Institute of Parasitology and Biomedicine López-Neyra, P.T. Health Sciences, Avd del Conocimiento s/n, 18100, Armilla, Granada, Spain
Tzanakis NE, Tsiligianni IG, Siafakas NM. Pulmonary involvement and allergic disorders in inflammatory bowel disease. World J Gastroenterol 2010; 16(3): 299-305 Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i3/299.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i3.299
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major forms of chronic relapsing inflammatory bowel disease (IBD). Apart from overlapping epidemiological, clinical, radiological, endoscopic and histological characteristics[1,2] between UC and CD, there are clear differences in the extent of inflammation in the gastrointestinal tract and in several immunological parameters[3-5] suggesting that they are distinct disease processes. The pathogenesis of IBD seems to be more complex than one single cause and probably involves an interaction between genetic predisposing factors[6-8], exogenous and endogenous triggers[3,9-14], and modifying factors[3,15,16]. The outcome of these interactions is a spontaneously relapsing and remitting inflammatory process in intestinal mucosa associated with recruitment and activation of lymphocytes, macrophages and other inflammatory cells[3,17-20].
Extraintestinal and systemic manifestations occur frequently in patients with IBD[20-25]. These various disease states can be diagnosed before, concomitant with, or after the diagnosis of a specific type of IBD. Two large case studies have demonstrated that between 25% and 36% of patients with either type of idiopathic IBD will have at least one such associated disease[22-23]. Yamamoto-Furusho et al found that extraintestinal manifestations were present in 41.5% of 848 cases with UC. More than 100 systemic complications involving almost every organ system in the body have been described. The spectrum, the frequency and the temporal relation of the complications have led to the hypothesis that IBD is a systemic disorder[22-23,26].
IBD is associated with a wide variety of extraintestinal lesions in many organs and over some decades the pattern has changed and the lung is regarded as one of these affected organs[21,26-31]. In recent years a few hundred cases with pulmonary involvement and IBD have been reported and in that way pulmonary involvement has been proved to be common. A growing number of studies in the literature have reported either clinical or latent pulmonary involvement in patients with IBD[29,31-34]. In this review we will focus on the extraintestinal manifestations that are associated with lungs and airways. In an attempt to classify the reported lung manifestations in patients with IBD in a more useful way, the manifestations were distinguished as follows: (1) involvement of airways; (2) pulmonary function testing abnormalities; and (3) diffuse or localized interstitial lung complications caused by either disease or treatment received. Finally, studies regarding the relationship between allergy and IBD will be discussed in detail.
IBD AND AIRWAYS
The manifestations of IBD in airways include, chronic bronchial suppuration particularly in patients with UC[31,34-36], bronchiectasis[32,37-40], localized obstruction of upper airways, bronchiolitis obliterans organizing pneumonia[32,42,43], granulomatous bronchiolitis, tracheobronchitis[45,46], bronchiolitis obliterans, tracheobronchial stenosis and diffuse obstructive disease[34,49]. Obstructive disease was not confirmed in some studies. An increased risk of both UC and CD in chronic obstructive pulmonary disease (COPD) patients has been reported in some studies, focusing attention on the association between airway diseases (AD) and IBD. We have reported a small airway dysfunction, detected by density dependence methods, in patients with IBD. In the study by Louis et al, patients with IBD, free of pulmonary symptoms, independently of the presence of atopy, showed bronchial hyperresponsiveness. This interesting finding could lead to the hypothesis that local mucosal inflammation in the intestine is responsible for the mild airway inflammation and not atopy. This hypothesis is not new. Basal cell hyperplasia, membrane thickening and submucosal inflammation have been reported in patients with UC and bronchial suppuration. CD may affect the oral cavity and the colon[26,54,55] while both UC[34,41] and CD have been reported to involve the larynx. There are also some morphological and developmental similarities between colonic and bronchial epithelium. Both are derived from the primitive gut, whereas the lungs arise from the laryngo-tracheal bud. Both are composed of columnar epithelium with goblet cells and submucosal mucous glands. Furthermore, there is increasing evidence that an immune system specific to the gastrointestinal tract common to all mucosal surfaces exists, in which lymphocytes are sensitized to antigens at one mucosal site and by circulation are localized and produce inflammation in other mucosal surfaces[53,58-61].
PULMONARY FUNCTION TESTING ABNORMALITIES
Previous reports concerning pulmonary function abnormalities in patients with IBD are conflicting. In some studies no differences in pulmonary function tests (PFTs) between patients with IBD and the control group were found[49,62]. In the study by Neilly et al airway obstruction was the most common finding affecting patients with CD (45%). However, the indices of airway obstruction were not significantly different from those obtained in age-, sex- and smoking-matched controls. As discussed above, Louis et al reported an increased bronchial responsiveness in IBD patients, while the baseline lung function tests were within the normal range. In the study by Mohamed-Hussein et al, fifteen out of 26 patients with UC had an important impairment in PFTs. In the study by Herrlinger et al, the impairment in PFTs was more pronounced in IBD patients with active disease than in those with inactive disease.
Pulmonary diffusion capacity (TLCO) is often impaired in IBD patients. Heatley et al found an increased prevalence of TLCO impairment in 25% of patients with CD. Reduction of TLCO in patients with IBD has been reported in various studies[61,64,66-69]. Eade et al and Bonniere et al found that the reduced TLCO or other PFTs parameters were not correlated with the location and severity of IBD or with the concurrent medication mode[59,66]. We examined 132 patients, 47 (17 female, 30 male) with CD and 85 (35 female, 50 male) mean age 40 years with UC. The main finding of our study was a high prevalence of impaired TLCO in patients with CD and UC suggesting involvement of the lung parenchyma. All other PFTs parameters were abnormal in a high percentage of patients, however, they did not show statistically significant differences from those in the control group. Our data suggest that the impairment of TLCO was statistically significantly higher in patients with exacerbation of disease than in remission. This finding is in accordance with other studies[61,65,68-70] which reported a higher prevalence of impaired TLCO among patients with active IBD disease as compared to patients in remission. In contrast, Douglas et al reported a reduced gas transfer factor in 16% of 44 patients with IBD but these abnormalities were not related to disease activity. The reduction in gas transfer factor indicates damage to lung parenchyma. The nature of this lung involvement remains debatable. However, some explanations will be discussed in the following section concerning the relationship between IBD and interstitial lung complications.
INTERSTITIAL LUNG COMPLICATIONS
Interstitial lung involvement has been reported to accompany both clinical IBD entities, UC[72-78] and CD[79-83]. The interstitial lung infiltrates have been proven histologically to be either pulmonary vasculitis[76,77,84] or more often granulomatous disease[74,79,80,82,83,85,86]. Treatment with corticosteroids[75,78] or with appropriate medication such as sulfasalazine or mesalamine for the basic gastrointestinal disease appeared to be satisfactory for both diseases. Pneumonitis, in contrast, due either to sulphasalazine or mesalamine is a well-recognized adverse drug reaction in these patients[50,87-95].
The above observations and the histological similarities between CD and sarcoidosis in particular, have led several groups to investigate the number and types of cells recovered by bronchoalveolar lavage (BAL)[58,59,96]. An increased percentage of alveolar lymphocytes was reported in the study by Wallaert et al in patients with CD. In the same study, a correlation between BAL differential cell count and PFTs abnormalities, drug treatment or CD site and activity was not reported. The same group reported an increased level of IgG and IgM in BAL recovered from patients with alveolitis but not in those with normal BAL. This observation of subclinical alveolitis was confirmed in the study by Bonniere and associates in 22 patients with CD. In the same study, a significant increase in superoxide anion production by alveolar macrophages related to spontaneous activation and alteration of pulmonary function was observed[59,98]. Bartholo et al found lymphocytosis in induced sputum of patients with CD even without pulmonary symptoms. Raj et al reported a trend for higher lymphocyte counts in the sputum of patients with CD compared with UC. Smiéjan et al reported lymphocytosis alveolitis in patients with CD but not in patients with other inflammatory bowel disorders including UC. In the same study, an increase in the CD4 lymphocyte subset (increased ratio of CD4/CD8) was found in patients with an active stage of CD similar to patients with sarcoidosis. Yamaguchi et al reported increased BAL lymphocytes with an elevated CD4/CD8 ratio and enhanced expression of CD2 antigen in lung T cells in 8 patients with CD. Ussov et al found a significant increase in the pulmonary vascular granulocyte pool in patients with CD. The meaning of this subclinical alveolitis and alterations in lung parenchyma is unclear. A subclinical inflammatory alveolitis as assessed by BAL cell analysis may be present in asymptomatic patients with immunological systemic disorders and with normal chest X-ray. The fact that pulmonary involvement is not as common during extrathoracic granulomatosis as CD, whereas subclinical alveolitis is frequent, suggests that the lung possibly downregulates, in some way, alveolar inflammation due to the systemic immune disorder. The alveolitis observed in IBD patients does not necessarily precede the development of pulmonary granulomatosis and fibrosis[97,103]. Increased pulmonary permeability to diethylenetriaminepenta-acetate radiolabelled with 99m-technetium (99mTc-DTPA) related to abnormal BAL findings has also been reported in patients with CD. The reduction in diffusing capacity of the lungs (DLCO) is common and early manifestations of interstitial lung diseases[64,68,97] and latent lymphocytosis alveolitis could explain, in part, the reduction in DLCO observed in patients with CD.
ATOPY AND IBD
The gastrointestinal tract comes into direct contact with a great variety of foreign substances and under certain conditions these may act as antigens causing allergic reactions. On the other hand, atopic subjects are possibly susceptible to several inhalants or food allergens, while clinical features of atopic disorders include many organs among them both the pulmonary and gastrointestinal systems. Hippocrates reported that milk could cause gastric upset and urticaria and was probably the first to relate general atopy with gastrointestinal allergy. Hammer et al found an increased prevalence of all atopic features. Asthma was also documented as being highly prevalent in a large study by Bernstein et al. Studies on the relation between IBD and atopy are listed in Table 1. Ceyhan et al reported that allergic symptoms and skin prick test positivity were more common in IBD patients (Table 1). Fireman et al reported a higher percentage of eosinophils in induced sputum in patients with UC. Several studies have tried to investigate the attractive hypothesis that IBD, in particular UC, may be an allergic response to food[111,112] especially in individuals susceptible to various allergens. This hypothesis is supported by certain evidence that eosinophils and eosinophil-derived mediators contribute to the histopathology and pathophysiology of IBD[19,113-116]. Most studies confirmed the observation that atopic features are more frequent in patients with IBD than in the general population[114,117-120] (Table 1). This may be an explanation for the overlapping allergic disorders in both the respiratory and gastrointestinal systems. However, the frequency of bronchial hyperresponsiveness was significantly higher in IBD patients than in normal subjects (41% vs 5%), even when non-atopic subjects were considered. This finding is consistent with the hypothesis that another immune system common to both exists and may be responsible for the inflammation in both systems. Only one study by Troncone et al showed that there was no correlation between atopy and IBD.
Engkilde et al found an inverse association between a contact allergy and IBD. In this study although there was a chronic contact allergic dermatitis which was considered by the authors to have a Th2 profile, contact allergy has a Th1 profile. Engkilde et al suggested that this may be due to shared genetic factors, common environmental determinants or skewness of the immune system. Medoff et al suggested that T cell trafficking takes place in peripheral tissue in allergic asthma. It is suggested that this trafficking may involve several interactions between innate immune cells and T cells. Several explanations for this phenomenon have been given over the years, however, no definite conclusions have been reached. Hammer et al suggested a genetic predisposition, Myrelid et al implicated TNF mast cells and D’Arienzo et al suggested a Th2 or Th1 helper response. The mechanisms of atopy in IBD merit further investigation.
Three patterns of pulmonary involvement have been reported to accompany IBD: (1) airway disease including large airway stenosis, chronic bronchitis, small airway dysfunction, severe bronchial suppuration and bronchiectasis; (2) parenchymal lung involvement either as subclinical lymphocytic alveolitis or several types of pulmonary infiltrate such as granulomatous bronchiolitis and bronchiolitis obliterans; and (3) a reduction in the diffusing capacity of the lung is a well established abnormality of pulmonary function testing in some patients with IBD.
We propose that patients suffering from IBD should undergo pulmonary evaluation which should include physical examination, chest X-ray and pulmonary function testing with DLCO measurement. This pulmonary evaluation may be useful in detecting subclinical or clinical pulmonary involvement in IBD patients or as a baseline evaluation. In clinical cases with pulmonary manifestations, inhaled or systemically administered steroids appear to be an effective treatment. With regard to atopy, routine investigations should be considered, at least in patients with IBD who also present with airway dysfunction.
2 Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991; 325: 928-937 PubMed
4 Shanahan F. The role of autoantibodies and autoimmunity in chronic inflammatory disorders of the gut. Current Opin Gastroenterol 1992; 8: 988-992 DOI
6 Taylor K, Rotter J, Yang H, Targan S, Shanahan F, Karp L. The genetics of inflammatory bowel disease. Inflammatory bowel disease: from bench to bedside. 2nd edition.Baltimore: Williams & Wilkins, 1993: 21-65
8 Yamamoto-Furusho JK. Genetic factors associated with the development of inflammatory bowel disease. World J Gastroenterol 2007; 13: 5594-5597 PubMed
11 Järnerot G, Lindberg E, Tysk C. Smoking and inflammatory bowel disease. Gastroenterol Hepatol 1995; 18: 507-509 PubMed
13 Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996; 43: 381-393 PubMed
15 Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The stress response and the regulation of inflammatory disease. Ann Intern Med 1992; 117: 854-866 PubMed
18 Hommes DW, Meenan J, de Haas M, ten Kate FJ, von dem Borne AE, Tytgat GN, van Deventer SJ. Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut 1996; 38: 564-567 PubMed
20 Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang Z, Kan Q, Liu Z, Liu Y. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1133-1144 PubMed
21 Levine JB, Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am 1995; 24: 633-646 PubMed
22 Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77: 914-920 PubMed
23 Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55: 401-412 PubMed
25 Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-4831 PubMed
26 Rankin GB. Extraintestinal and systemic manifestations of inflammatory bowel disease. Med Clin North Am 1990; 74: 39-50 PubMed
28 Podolsky DK. Inflammatory bowel disease (2). N Engl J Med 1991; 325: 1008-1016 PubMed
33 Casey MB, Tazelaar HD, Myers JL, Hunninghake GW, Kakar S, Kalra SX, Ashton R, Colby TV. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003; 27: 213-219 PubMed
35 Butland RJ, Cole P, Citron KM, Turner-Warwick M. Chronic bronchial suppuration and inflammatory bowel disease. Q J Med 1981; 50: 63-75 PubMed
37 Garg K, Lynch DA, Newell JD. Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features. J Thorac Imaging 1993; 8: 159-163 PubMed
38 Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Fukukita S, Tsutsui K, Imoto I, Suzuki S, Kitagawa T. Bronchopulmonary disease in ulcerative colitis. Intern Med 1992; 31: 1155-1159 PubMed DOI
40 Eaton TE, Lambie N, Wells AU. Bronchiectasis following colectomy for Crohn's disease. Thorax 1998; 53: 529-531 PubMed
44 Vandenplas O, Casel S, Delos M, Trigaux JP, Melange M, Marchand E. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158: 1676-1679 PubMed
46 Shad JA, Sharieff GQ. Tracheobronchitis as an initial presentation of ulcerative colitis. J Clin Gastroenterol 2001; 33: 161-163 PubMed
48 Kuźniar T, Sleiman C, Brugière O, Groussard O, Mal H, Mellot F, Pariente R, Malolepszy J, Fournier M. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J 2000; 15: 209-212 PubMed DOI
52 Tzanakis N, Samiou M, Bouros D, Mouzas J, Kouroumalis E, Siafakas NM. Small airways function in patients with inflammatory bowel disease. Am J Respir Crit Care Med 1998; 157: 382-386 PubMed
53 Louis E, Louis R, Drion V, Bonnet V, Lamproye A, Radermecker M, Belaiche J. Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease. Allergy 1995; 50: 729-733 PubMed DOI
54 Lisciandrano D, Ranzi T, Carrassi A, Sardella A, Campanini MC, Velio P, Bianchi PA. Prevalence of oral lesions in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 7-10 PubMed
55 Case records of the Massachusetts General Hospital. Case 29-1967. N Engl J Med 1967; 277: 92-101 PubMed
56 Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-1978. N Engl J Med 1978; 299: 538-544 PubMed
57 Bienenstock J. Cellular communication networks. Implications for our understanding of gastrointestinal physiology. Ann N Y Acad Sci 1992; 664: 1-9 PubMed
59 Bonniere P, Wallaert B, Cortot A, Marchandise X, Riou Y, Tonnel AB, Colombel JF, Voisin C, Paris JC. Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut 1986; 27: 919-925 PubMed DOI
61 Overdahl MC, Julian MW, Weisbrode SE, Davis WB, Dorinsky PM. Paraaminosalicylate blocks that ileal injury induced by phorbol myristate acetate. Am J Respir Crit Care Med 1994; 149: 1640-1647 PubMed
63 Mohamed-Hussein AA, Mohamed NA, Ibrahim ME. Changes in pulmonary function in patients with ulcerative colitis. Respir Med 2007; 101: 977-982 PubMed
64 Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002; 97: 377-381 PubMed DOI
65 Heatley RV, Thomas P, Prokipchuk EJ, Gauldie J, Sieniewicz DJ, Bienenstock J. Pulmonary function abnormalities in patients with inflammatory bowel disease. Q J Med 1982; 51: 241-250 PubMed
66 Eade OE, Smith CL, Alexander JR, Whorwell PJ. Pulmonary function in patients with inflammatory bowel disease. Am J Gastroenterol 1980; 73: 154-156 PubMed
67 Sethy PK, Dutta U, Aggrawal AN, Das R, Gulati M, Sinha SK, Singh K. Pulmonary and hematological alterations in idiopathic ulcerative colitis. Indian J Gastroenterol 2003; 22: 176-179 PubMed
68 Marvisi M, Borrello PD, Brianti M, Fornarsari G, Marani G, Guariglia A. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J 2000; 16: 965-968 PubMed DOI
69 Songür N, Songür Y, Tüzün M, Doğan I, Tüzün D, Ensari A, Hekimoglu B. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol 2003; 37: 292-298 PubMed
71 Douglas JG, McDonald CF, Leslie MJ, Gillon J, Crompton GK, McHardy GJ. Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? Respir Med 1989; 83: 389-394 PubMed DOI
72 Theodoropoulos G, Archimandritis A, Davaris P, Plataris J, Melissinos K. Ulcerative colitis and sarcoidosis: a curious association-report of a case. Dis Colon Rectum 1981; 24: 308-310 PubMed
76 Isenberg JI, Goldstein H, Korn AR, Ozeran RS, Rosen V. Pulmonary vasculitis--an uncommon complication of ulcerative colitis. Report of a case. N Engl J Med 1968; 279: 1376-1377 PubMed
82 Le Roux P, Boulloche J, Briquet MT, Guyonnaud CD, Le Luyer B. [Respiratory manifestation of Crohn's disease. Apropos of a case in an adolescent] Rev Mal Respir 1995; 12: 59-61 PubMed
83 Kayser K, Probst F, Gabius HJ, Müller KM. Are there characteristic alterations in lung tissue associated with Crohn's disease? Pathol Res Pract 1990; 186: 485-490 PubMed
84 Collins WJ, Bendig DW, Taylor WF. Pulmonary vasculitis complicating childhood ulcerative colitis. Gastroenterology 1979; 77: 1091-1093 PubMed
85 McKee AL, Rajapaksa A, Kalish PE, Pitchumoni CS. Severe interstitial pulmonary fibrosis in a patient with chronic ulcerative colitis. Am J Gastroenterol 1983; 78: 86-89 PubMed
86 Meadway J. Ulcerative colitis, colitic spondylitis and associated apical pulmonary fibrosis. Proc R Soc Med 1974; 67: 324-325 PubMed
90 Yaffe BH, Korelitz BI. Sulfasalazine pneumonitis. Am J Gastroenterol 1983; 78: 493-494 PubMed
93 Sebastian Domingo JJ, Ventura A, Pérez de Ayala V, Castellanos D. Hypersensitivity pneumonitis by sulphasalazine. Allergy 1989; 44: 522 PubMed
94 Sviri S, Gafanovich I, Kramer MR, Tsvang E, Ben-Chetrit E. Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. J Clin Gastroenterol 1997; 24: 34-36 PubMed
95 Guslandi M. Respiratory distress during mesalamine therapy. Dig Dis Sci 1999; 44: 48-49 PubMed
96 Smiéjan JM, Cosnes J, Chollet-Martin S, Soler P, Basset FM, Le Quintrec Y, Hance AJ. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104: 17-21 PubMed
97 Wallaert B, Dugas M, Dansin E, Perez T, Marquette CH, Ramon P, Tonnel AB, Voisin C. Subclinical alveolitis in immunological systemic disorders. Transition between health and disease? Eur Respir J 1990; 3: 1206-1216 PubMed
98 Wallaert B, Aerts C, Bonniere P, Cortot A, Tonnel AB, Paris JC, Voisin C. Superoxide anion generation by alveolar macrophages in Crohn's disease. N Engl J Med 1985; 312: 444-445 PubMed
99 Bartholo RM, Zaltman C, Elia C, Cardoso AP, Flores V, Lago P, Cassabian L, Dorileo FC, Lapa-e-Silva JR. Bronchial hyperresponsiveness and analysis of induced sputum cells in Crohn's disease. Braz J Med Biol Res 2005; 38: 197-203 PubMed DOI
101 Yamaguchi E, Okazaki N, Itoh A, Furuya K, Abe S, Kawakami Y. Enhanced expression of CD2 antigen on lung T cells. Am Rev Respir Dis 1991; 143: 829-833 PubMed
102 Ussov WY, Peters AM, Glass DM, Gunasekera RD, Hughes JM. Measurement of the pulmonary vascular granulocyte pool. J Appl Physiol 1995; 78: 1388-1395 PubMed
105 Zanjanian MH. The intestine in allergic diseases. Ann Allergy 1976; 37: 208-218 PubMed
106 Siegel J. Inflammatory bowel disease: another possible effect of the allergic diathesis. Ann Allergy 1981; 47: 92-94 PubMed
110 Fireman E, Masarwy F, Groisman G, Shtark M, Kopelman Y, Kivity S, Fireman Z. Induced sputum eosinophilia in ulcerative colitis patients: the lung as a mirror image of intestine? Respir Med 2009; 103: 1025-1032 PubMed DOI
111 Smart HL, Mayberry JF. Atopy, food and ulcerative colitis. Hepatogastroenterology 1986; 33: 47-48 PubMed
112 Glassman MS, Newman LJ, Berezin S, Gryboski JD. Cow's milk protein sensitivity during infancy in patients with inflammatory bowel disease. Am J Gastroenterol 1990; 85: 838-840 PubMed
114 Levo Y, Shalit M, Wollner S, Fich A. Serum IgE levels in patients with inflammatory bowel disease. Ann Allergy 1986; 56: 85-87 PubMed
115 Berstad A, Børkje B, Riedel B, Elsayed S, Berstad A. Increased fecal eosinophil cationic protein in inflammatory bowel disease. Hepatogastroenterology 1993; 40: 276-278 PubMed
116 Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996; 2: 449-456 PubMed DOI
119 Mee AS, Brown D, Jewell DP. Atopy in inflammatory bowel disease. Scand J Gastroenterol 1979; 14: 743-746 PubMed
124 Myrelid P, Dufmats M, Lilja I, Grinn C, Lannerstad O, Sjödahl R. Atopic manifestations are more common in patients with Crohn disease than in the general population. Scand J Gastroenterol 2004; 39: 731-736 PubMed
125 D'Arienzo A, Manguso F, Astarita C, D'Armiento FP, Scarpa R, Gargano D, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol 2000; 35: 624-631 PubMed
S- Editor Wang YR L- Editor Webster JR E- Editor Lin YP